PRMT5 critically mediates TMAO-induced inflammatory response in vascular smooth muscle cells

Cell Death Dis. 2022 Apr 4;13(4):299. doi: 10.1038/s41419-022-04719-7.

Abstract

A high plasma level of the choline-derived metabolite trimethylamine N-oxide (TMAO) is closely related to the development of cardiovascular disease. However, the underlying mechanism remains unclear. In the present study, we demonstrated that a positive correlation of protein arginine methyltransferase 5 (PRMT5) expression and TMAO-induced vascular inflammation, with upregulated vascular cell adhesion molecule-1 (VCAM-1) expression in primary rat and human vascular smooth muscle cells (VSMC) in vitro. Knockdown of PRMT5 suppressed VCAM-1 expression and the adhesion of primary bone marrow-derived macrophages to TMAO-stimulated VSMC. VSMC-specific PRMT5 knockout inhibited vascular inflammation with decreased expression of VCAM-1 in mice. We further identified that PRMT5 promoted VCAM-1 expression via symmetrical demethylation of Nuclear factor-κB p65 on arginine 30 (R30). Finally, we found that TMAO markedly induced the expression of nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4) and production of reactive oxygen species, which contributed to PRMT5 expression and subsequent VCAM-1 expression. Collectively, our data provide novel evidence to establish a Nox4-PRMT5-VCAM-1 in mediating TMAO-induced VSMC inflammation. PRMT5 may be a potential target for the treatment of TMAO-induced vascular diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Inflammation / genetics
  • Inflammation / metabolism
  • Methylamines / metabolism
  • Methylamines / pharmacology
  • Mice
  • Muscle, Smooth, Vascular* / metabolism
  • Rats
  • Vascular Cell Adhesion Molecule-1* / genetics
  • Vascular Cell Adhesion Molecule-1* / metabolism

Substances

  • Methylamines
  • Vascular Cell Adhesion Molecule-1
  • trimethyloxamine